Replies to post #166058 on Biotech Values

[goochbart]

Trius, Optimer, now ASTX go for less than worth IMO. Are these companies being surrendered to bidders and the management being rewarded inordinately to go along?

[DewDiligence]

A few other biotechs have held CC’s with no Q&A session, although most of them were lower-quality companies than ASTX.

[DewDiligence]

FDA grants ODD for Otsuka’s Guadecitabine in AML:

http://finance.yahoo.com/news/astex-pharmaceuticals-announces-orphan-drug-164700307.html